Improving cancer survival by optimising drug exposure at sites of cancer metastasis

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1105383

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The metastatic spread of cancer is responsible for 90% of cancer related deaths. While the standard of care is to administer high doses of toxic drugs to kill the cancer, this often leads to life threatening side effects without guarantee of a cure. This work is aimed at identifying how nanometer sized chemotherapeutic ‘nanomedicines’ can be optimally developed to enhance drug targeting towards sites of tumour growth and metastasis and maximise therapeutic success whilst limiting side effects.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2019

Funding Scheme: Career Development Fellowships

Funding Amount: $463,652.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Pharmaceutical Sciences

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer chemotherapeutic agents | cancer metastasis | drug delivery systems | nanotechnology | pharmacokinetics

Related Links